2007 Annual Meeting | Stroke Prevention in 2007

Date Monday 04/30/07

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Mitchell S. Elkind, MD, MS, FAAN

Topic(s)

Learning Objectives Participants should be able to apply recent evidence on use of statins, ACE inhibitors, ARBs, and other antihypertensive agents to reduce stroke risk; discuss recent trials of carotid surgery and stenting and provide a rationale for interventional treatment of intracranial stenosis; choose appropriately among the different antithrombotic agents for stroke prevention, including aspirin, clopidogrel, dipyridamole, and warfarin; and decide between medical and surgical management in individual patients with patent foramen ovale.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
09:00 AM - 09:45 AM		Statins, ACE Inhibitors, and ARBs: New Ways to Reduce Stroke Risk Mitchell S. Elkind, MD, MS, FAAN
09:45 AM - 10:30 AM		Endarterectomy and Stenting: Here, There, and Everywhere Pierre Fayad, MD, FAHA, FAAN
10:30 AM - 10:45 AM		Break
10:45 AM - 11:30 AM		From Anticoagulants to Antiplatelets: Where Are We Now? J. D. Easton, MD, FAAN
11:30 AM - 12:15 PM		Patent Foramen Ovale: To Close or Not to Close? Steven R. Messe, MD, FAHA, FAAN
12:15 PM - 12:45 PM		Questions and Answers

Faculty Disclosures
Mitchell S. Elkind, MD, MS, FAAN	Dr. Elkind has received personal compensation for serving as an employee of American Heart Association. Dr. Elkind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atria Academy.
Pierre Fayad, MD, FAHA, FAAN	Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
J. D. Easton, MD, FAAN	No disclosure on file
Steven R. Messe, MD, FAHA, FAAN	Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.

��ɫ��

��ɫ��